RY 171.23 -1.0746% SHOP 170.14 2.1432% TD 81.85 -0.7879% ENB 62.92 0.5594% BN 84.78 -1.8636% TRI 244.07 -0.9215% CNQ 44.44 1.6236% CP 111.16 2.0753% CNR 147.09 2.2595% BMO 140.35 -1.2315% BNS 72.0 -0.0971% CSU 4795.7002 -0.5041% CM 88.52 1.351% MFC 42.53 -0.3047% ATD 76.2 1.3163% NGT 62.42 -0.5893% TRP 66.63 1.0005% SU 55.02 0.5299% WCN 269.74 -1.0927% L 182.96 1.4416%
Last update at 2025-02-04T18:57:00Z
Is Thermo Fisher Scientific (TMO) the Best Cancer Stock to Buy According to Hedge Funds?
Sun 02 Feb 25, 09:16 PMQ4 2024 Thermo Fisher Scientific Inc Earnings Call
Fri 31 Jan 25, 04:21 AMThermo Fisher Scientific Gaps Up And Nears A Buy Point On Strong Earnings Beat
Thu 30 Jan 25, 09:25 PMThermo Fisher’s (NYSE:TMO) Q4 Sales Beat Estimates
Thu 30 Jan 25, 09:18 PMThermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up
Thu 30 Jan 25, 04:28 PMThermo Fisher (TMO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Thu 30 Jan 25, 02:30 PMWhy Thermo Fisher Scientific (TMO) Is the Best Stock to Buy in 2025 for Beginners
Thu 30 Jan 25, 12:21 PMThermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates
Thu 30 Jan 25, 12:10 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7835.00M | 8841.00M | 7225.00M | 4070.00M | 3262.00M |
| Minority interest | -10.00000M | -3.00000M | - | - | - |
| Net income | 6950.00M | 7725.00M | 6375.00M | 3696.00M | 2938.00M |
| Selling general administrative | 7127.00M | 6842.00M | 6930.00M | 6144.00M | 6057.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 19500.00M | 20234.00M | 16505.00M | 11827.00M | 11364.00M |
| Reconciled depreciation | 3381.00M | 2592.00M | 2325.00M | 2277.00M | 2267.00M |
| Ebit | 8393.00M | 10028.00M | 7794.00M | 4594.00M | 3979.00M |
| Ebitda | 12056.00M | 12166.00M | 10202.00M | 6610.00M | 6246.00M |
| Depreciation and amortization | 3663.00M | 2138.00M | 2408.00M | 2016.00M | 2267.00M |
| Non operating income net other | -4.00000M | -655.00000M | -16.00000M | 152.00M | - |
| Operating income | 8393.00M | 10028.00M | 7794.00M | 4594.00M | 3783.00M |
| Other operating expenses | 36408.00M | 28986.00M | 24325.00M | 21361.00M | 20525.00M |
| Interest expense | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M |
| Tax provision | 703.00M | 1109.00M | 850.00M | 374.00M | 324.00M |
| Interest income | 272.00M | 43.00M | 488.00M | 224.00M | 137.00M |
| Net interest income | -454.00000M | -493.00000M | -488.00000M | -452.00000M | -530.00000M |
| Extraordinary items | - | - | 0.00000M | -8.00000M | -117.00000M |
| Non recurring | 114.00M | 197.00M | 99.00M | -413.00000M | 50.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 703.00M | 1109.00M | 850.00M | 374.00M | 324.00M |
| Total revenue | 44915.00M | 39211.00M | 32218.00M | 25542.00M | 24358.00M |
| Total operating expenses | 10993.00M | 10009.00M | 8612.00M | 7646.00M | 7531.00M |
| Cost of revenue | 25415.00M | 18977.00M | 15713.00M | 13715.00M | 12994.00M |
| Total other income expense net | -558.00000M | -1187.00000M | -569.00000M | -524.00000M | -41.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6960.00M | 7728.00M | 6375.00M | 3696.00M | 2938.00M |
| Net income applicable to common shares | 6950.00M | 7725.00M | 6375.00M | 3696.00M | 2938.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 97154.00M | 95123.00M | 69052.00M | 58381.00M | 56232.00M |
| Intangible assets | 17478.00M | 20146.00M | 12685.00M | 14014.00M | 14978.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1644.00M | 1640.00M | 1131.00M | 1172.00M | 922.00M |
| Total liab | 53006.00M | 54146.00M | 34535.00M | 28706.00M | 28646.00M |
| Total stockholder equity | 43978.00M | 40793.00M | 34507.00M | 29675.00M | 27586.00M |
| Deferred long term liab | 2849.00M | 3837.00M | 1794.00M | 2192.00M | 2265.00M |
| Other current liab | 5449.00M | 5377.00M | 4230.00M | 2685.00M | 4532.00M |
| Common stock | 441.00M | 439.00M | 437.00M | 434.00M | 432.00M |
| Capital stock | 441.00M | 439.00M | 437.00M | 434.00M | 432.00M |
| Retained earnings | 41910.00M | 35431.00M | 28116.00M | 22092.00M | 18696.00M |
| Other liab | 5689.00M | 8138.00M | 5134.00M | 4849.00M | 4651.00M |
| Good will | 41196.00M | 41924.00M | 26041.00M | 25714.00M | 25347.00M |
| Other assets | 2224.00M | 3013.00M | 1629.00M | 1245.00M | 1053.00M |
| Cash | 8524.00M | 4477.00M | 10325.00M | 2399.00M | 2103.00M |
| Cash and equivalents | 8524.00M | 4477.00M | 10325.00M | 2399.00M | 2103.00M |
| Total current liabilities | 17010.00M | 13436.00M | 10304.00M | 6197.00M | 6147.00M |
| Current deferred revenue | 2601.00M | 2655.00M | 1271.00M | 916.00M | 809.00M |
| Net debt | 25964.00M | 30393.00M | 11410.00M | 15353.00M | 16887.00M |
| Short term debt | 5579.00M | 2537.00M | 2628.00M | 676.00M | 1271.00M |
| Short long term debt | 5579.00M | 2537.00M | 2628.00M | 676.00M | 1271.00M |
| Short long term debt total | 34488.00M | 34870.00M | 21735.00M | 17752.00M | 18990.00M |
| Other stockholder equity | 1627.00M | 4923.00M | 5954.00M | 7149.00M | 8458.00M |
| Property plant equipment | 9280.00M | 8333.00M | 5912.00M | 4749.00M | 4165.00M |
| Total current assets | 25229.00M | 20113.00M | 21957.00M | 11893.00M | 10625.00M |
| Long term investments | - | - | - | 67.00M | 64.00M |
| Net tangible assets | -14544.00000M | -21182.00000M | -4219.00000M | -10053.00000M | -12739.00000M |
| Short term investments | 2.00M | - | 28.00M | 37.00M | 31.00M |
| Net receivables | 9427.00M | 8945.00M | 6472.00M | 4952.00M | 4595.00M |
| Long term debt | 28909.00M | 32333.00M | 19107.00M | 17076.00M | 17719.00M |
| Inventory | 5634.00M | 5051.00M | 4029.00M | 3370.00M | 3005.00M |
| Accounts payable | 3381.00M | 2867.00M | 2175.00M | 1920.00M | 1615.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 54.00M | 62.00M | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3099.00000M | -2329.00000M | -2807.00000M | -2679.00000M | -2498.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 441.00M | 439.00M | 437.00M | 434.00M | 432.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 41910.00M | 35431.00M | 28116.00M | 22092.00M | 18696.00M |
| Treasury stock | - | -8922.00000M | -6818.00000M | -5236.00000M | -3665.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -2849.00000M | 4352.00M | 2457.00M | 1850.00M | 1051.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 69701.00M | 71997.00M | 45466.00M | 45243.00M | 44554.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 28909.00M | 32333.00M | 19107.00M | 17076.00M | 17719.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2159.00000M | -21932.00000M | -1510.00000M | -1487.00000M | -1253.00000M |
| Change to liabilities | 648.00M | 479.00M | 59.00M | 476.00M | 159.00M |
| Total cashflows from investing activities | -2159.00000M | -21932.00000M | -1510.00000M | -1487.00000M | -1253.00000M |
| Net borrowings | 654.00M | 8911.00M | 2747.00M | -1405.00000M | -1556.00000M |
| Total cash from financing activities | -2810.00000M | 6581.00M | 959.00M | -3118.00000M | -2237.00000M |
| Change to operating activities | -442.00000M | -1558.00000M | -395.00000M | -248.00000M | -81.00000M |
| Net income | 6960.00M | 7728.00M | 6375.00M | 3696.00M | 2938.00M |
| Change in cash | 4046.00M | -5845.00000M | 7914.00M | 305.00M | 756.00M |
| Begin period cash flow | 4491.00M | 10336.00M | 2422.00M | 2117.00M | 1361.00M |
| End period cash flow | 8537.00M | 4491.00M | 10336.00M | 2422.00M | 2117.00M |
| Total cash from operating activities | 9154.00M | 9543.00M | 8289.00M | 4973.00M | 4543.00M |
| Issuance of capital stock | - | - | - | 153.00M | 0.00000M |
| Depreciation | 3381.00M | 2592.00M | 2325.00M | 2277.00M | 2267.00M |
| Other cashflows from investing activities | 84.00M | -34.00000M | -36.00000M | -561.00000M | -495.00000M |
| Dividends paid | -455.00000M | -395.00000M | -337.00000M | -297.00000M | 266.00M |
| Change to inventory | -825.00000M | -1065.00000M | -508.00000M | -458.00000M | -324.00000M |
| Change to account receivables | -430.00000M | -204.00000M | -1302.00000M | -225.00000M | -366.00000M |
| Sale purchase of stock | -3000.00000M | -2000.00000M | -1500.00000M | -1500.00000M | -500.00000M |
| Other cashflows from financing activities | 4710.00M | -91.00000M | -147.00000M | 8350.00M | 5699.00M |
| Change to netincome | -179.00000M | 781.00M | -112.00000M | -385.00000M | -185.00000M |
| Capital expenditures | 2243.00M | 2523.00M | 1474.00M | 926.00M | 758.00M |
| Change receivables | -430.00000M | -204.00000M | -1302.00000M | -225.00000M | -366.00000M |
| Cash flows other operating | -401.00000M | -724.00000M | 7827.00M | 3288.00M | 2992.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 4185.00M | -6039.00000M | 7738.00M | 368.00M | 1053.00M |
| Change in working capital | -1049.00000M | -1558.00000M | -395.00000M | -619.00000M | -530.00000M |
| Stock based compensation | 307.00M | 230.00M | 196.00M | 181.00M | 181.00M |
| Other non cash items | 550.00M | 957.00M | 340.00M | -214.00000M | 106.00M |
| Free cash flow | 6911.00M | 7020.00M | 6815.00M | 4047.00M | 3785.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
-11.855 2.00% | 581.89 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-1.26 0.59% | 213.00 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
-1.48 1.00% | 147.15 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
-6.27 1.34% | 462.77 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
0.22 0.11% | 199.33 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
168 Third Avenue, Waltham, MA, United States, 02451
| Name | Title | Year Born |
|---|---|---|
| Mr. Marc N. Casper | Chairman, Pres & CEO | 1968 |
| Mr. Stephen Williamson | Sr. VP & CFO | 1967 |
| Mr. Michel Lagarde | Exec. VP & COO | 1975 |
| Mr. Gianluca Pettiti | Exec. VP | 1979 |
| Mr. Joseph R. Holmes | VP & Chief Accounting Officer | 1980 |
| Mr. Ryan J. Snyder | Sr. VP & Chief Information Officer | NA |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | NA |
| Mr. Rafael Tejada | VP of Investor Relations | NA |
| Mr. Michael A. Boxer Esq. | Sr. VP, Gen. Counsel & Sec. | 1962 |
| Ms. Sandy B. Pound | VP & Chief Communications Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...